Edition:
United States

Amphastar Pharmaceuticals Inc (AMPH.OQ)

AMPH.OQ on NASDAQ Stock Exchange Global Select Market

19.30USD
15 Dec 2017
Change (% chg)

$0.57 (+3.04%)
Prev Close
$18.73
Open
$18.74
Day's High
$19.31
Day's Low
$18.74
Volume
384,418
Avg. Vol
92,454
52-wk High
$21.75
52-wk Low
$12.06

Chart for

About

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $887.33
Shares Outstanding(Mil.): 45.98
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

BRIEF-Amphastar Announces Approval For Medroxyprogesterone Acetate Injectable Suspension, USP

* AMPHASTAR ANNOUNCES APPROVAL FOR MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION, USP

Nov 29 2017

BRIEF-Amphastar Pharma reports results for three months ended Sept

* Amphastar Pharmaceuticals reports financial results for the three months ended September 30, 2017

Nov 08 2017

BRIEF-Amphastar Pharmaceuticals receives FDA approval for sodium bicarbonate injection

* Amphastar Pharmaceuticals receives FDA approval for sodium bicarbonate injection

Sep 20 2017

BRIEF-Amphastar Pharmaceuticals reports Q2 earnings per share $0.04

* Amphastar Pharmaceuticals reports financial results for the three months ended june 30, 2017

Aug 09 2017

BRIEF-Amphastar announces jury verdict in litigation against Momenta Pharmaceuticals and Sandoz Inc

* Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc

Jul 24 2017

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

Jul 21 2017

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

Jul 21 2017

UPDATE 2-U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON, July 21 A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

Jul 21 2017

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON, July 21 Amphastar Pharmaceuticals Inc on Friday won a trial in a lawsuit claiming that the drugmaker through its production of a generic version of the blood-thinner Lovenox infringed a patent held by Momenta Pharmaceuticals Inc.

Jul 21 2017

Momenta seeks $938 million from Amphastar at drug patent trial's end

A lawyer for Momenta Pharmaceuticals Inc urged a federal jury on Thursday to force Amphastar Pharmaceuticals Inc to pay $938 million for infringing a patent the drugmaker held through its production of a generic version of the blood-thinner Lovenox.

Jul 20 2017

Earnings vs. Estimates